Terbinafine hydrochloride is under clinical development by Moberg Pharma and currently in Phase III for Onychomycosis (Tinea Unguium). According to GlobalData, Phase III drugs for Onychomycosis (Tinea Unguium) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Terbinafine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Terbinafine hydrochloride overview

Terbinafine (MOB-015) is under development for the treatment of onychomycosis. The drug candidate is applied topically. It is an allylamine fungicidal agent. It targets squalene epoxidase.

Moberg Pharma overview

Moberg Pharma is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged nails, Fast relief of pain and itch, Waterproof liquid bandage, minor skin irritations, diaper rash, skin irritation and rash and dry feet and cracked heels in one step. The company works in collaboration to develop Oral mucositis for the treatment of pain in the oral cavity. It offers to license in and licensing out services. The company markets its products in Europe, South America, Africa, the Middle East and others. Moberg Pharma is headquartered in Stockholm, Sweden.

For a complete picture of Terbinafine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.